KNSA Kiniksa Pharmaceuticals Internationaldata gap · 76% coveragelimited data
Health Care · Pharmaceutical Preparations · close $78.59 (2026-10-16) · latest quarter in EDGAR: 2026-03-31
Kiniksa Pharmaceuticals International (KNSA) has a ThetaGrade House Rating of 63/100 (grade C), ranking #103 of 150 in Health Care. Its strongest pillars are balance sheet (84) and profitability (69); its weakest is valuation (24). Data gap: 4 factors without usable data, so 76% of the method weight is covered. TTM revenue growth is 56.7% and operating margin 12.4%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), Interest coverage. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 76% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 64| Revenue growth YoY (TTM) (22.2%) | 56.7% | 91 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | -9.4% | 9 |
Profitability
weight 18.5% (→20.0%) · 69| Operating margin (10.7%) | 12.4% | 48 |
| 4Q gross-margin change (9.3%) | 3.5% | 93 |
Balance sheet
weight 18.5% (→20.0%) · 84| Net debt / EBITDA (13.3%) | -2.00× | 92 |
| Current ratio (6.7%) | 3.79 | 68 |
| Interest coverage (0.0%)data gap | — | — |
Cash flow
weight 12.33% (→13.3%) · 58| FCF margin (6.7%) | 20.1% | 73 |
| FCF yield (6.7%) | 2.3% | 42 |
Valuation
weight 12.33% (→13.3%) · 24| P/E (inverted) (6.7%) | 86.36× | 11 |
| EV/Sales (inverted) (6.7%) | 7.72× | 36 |
Technicals (EOD)
| RSI(14) | 54.2 |
| EMA 9 / 21 | 78.54 / 77.82 |
| 200-day SMA | 58.04 |
| Volume vs 20d avg | 0.91× |
| 20-day return | -0.9% |
Exit-rule monitor
No exit or watch rules triggered.
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: Revenue − CostOfGoodsAndServicesSold · Operating income: OperatingIncomeLoss · D&A: DepreciationAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (us-gaap weighted basic shares, latest quarter (proxy)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like KNSA's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is KNSA's House Rating?
- KNSA scores 63 out of 100 (grade C) as of 2026-10-16, ranking #103 of 150 Health Care stocks we cover.
- What do analysts say about KNSA?
- We do not have enough analyst-sentiment data to score this stock.
- When does KNSA report earnings next?
- KNSA's next earnings report is estimated for about 2026-10-27 (window 2026-10-24 to 2026-10-30), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is KNSA a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology